Shots:

• The companies collaborated to evaluate Inspirna’s RGX-104 + BMS’ Yervoy in P-Ib/II expansion study for patients with metastatic endometrial cancer whose genomes holds E2 or E4 APOE genetic biomarker & who have progressed on prior checkpoint inhibitor therapy
• Inspirna will sponsor the study & will lead the study costs. RGX-104 is currently being evaluated in P-Ib/II trial in combination with SoC regimens for multiple lung cancer indications including SCLC & NSCLC & results are expected in H2’22
• In the P-I study, RGX-104 combination regimens showed a 60% response rate for cancers that had progressed on prior checkpoint inhibitor therapy & possessed the E2 or E4 APOE genetic biomarkers

Ref: Businesswire | Image: BMS